Tumor-targeted immuno-liposomes for delivery of therapeutics and diagnostics

Pharmaceutical Engineering

Volumn 26, Issue 5, 2006, Pages 96-104

  Elbayoumi, Tamer A ^a   Torchilin, Vladimir P ^b  

^a Center of Pharmaceutical Biotechnology and Nanomedicine   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOLIPOSOME; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; NONHUMAN; OVARY CANCER; REVIEW; TUMOR;

EID: 33749493339     PISSN: 02738139     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Torchilin, V.P. (2005). Recent Advances with Liposomes as Pharmaceutical Carriers. Nat Rev Drug Discov 4 (2), 145-160.
2. Allen, T.M. et al. (1991). Liposomes Containing Synthetic Lipid Derivatives of Poly(ethylene glycol) Show Prolonged Circulation Half-Lives in Vivo. Biochim Biophys Acta 1066 (1), 29-36.
3. Klibanov, A.L. et al. (1990). Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes. FEBS Lett 268 (1), 235-237.
4. Maeda, H. et al. (2000). Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review. J Control Release 65 (1-2), 271-284.
5. Gabizon, A. et al. (1994). Clinical Studies of Liposome-Encapsulated Doxorubicin. Acta Oncol 33 (7), 779-786.
6. Torchilin, V.P. (1996). Liposomes as Delivery Agents for Medical Imaging. Mol Med Today 2 (6), 242-249.
7. Tilcock, C. et al. (1989). Liposomal Gd-DTPA: Preparation and Characterization of Relaxivity. Radiology 171 (1), 77-80.
8. Ahkong, Q.F. and Tilcock, C. (1992). Attachment of 99mTc to Lipid Vesicles Containing the Lipophilic Chelate Dipalmitoylphosphatidylethanolamine- DTTA. Int J Rad Appl Instrum B 19 (8), 831-840.
9. Koukourakis, M.I. et al. (1999). Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer. J Clin Oncol 17 (11), 3512-3521.
10. Harrington, K.J. et al. (2001). Phase II Study of Pegylated Liposomal Doxorubicin (Caelyx) as Induction Chemotherapy for Patients with Squamous Cell Cancer of the Head and Neck. Eur J Cancer 37 (16), 2015-2022.
11. Iakoubov, L.Z. and Torchilin, V.P. (1997). A Novel Class of Antitumor Antibodies: Nucleosome-Restricted Antinuclear Autoantibodies (ANA) from Healthy Aged Nonautoimmune Mice. Oncol Res 9 (8), 439-446.
12. Iakoubov, L.Z. and Torchilin, V.P. (1998). Nucleosome-Releasing Treatment makes Surviving Tumor Cells Better Targets for Nucleosome-Specific Anticancer Antibodies. Cancer Detect Prev 22 (5), 470-475.
13. Chakilam, A.R., Pabba, S., Mongayt, D., Iakobouv, L.Z., Torchilin, V.P. (2004). A Single Monoclonal Antinuclear Autoantibody with Nucleosome-Restricted Specificity Inhibits the Growth of Diverse Human Tumors in Nude Mice. Cancer Therapy 2 (4), 353-364.
14. Lukyanov, A.N. et al. (2004). Tumor-Targeted Liposomes: Doxorubicin-Loaded Long-Circulating Liposomes Modified with Anti-Cancer Antibody. J Control Release 100 (1), 135-144.
15. Torchilin, V.P. et al. (2001). p-Nitrophenylcarbonyl-PEG-PE-Liposomes: Fast and Simple Attachment of Specific Ligands, including Monoclonal Antibodies, to Distal Ends of PEG Chains via p-nitrophenylcarbonyl Groups. Biochim Biophys Acta 1511 (2), 397-411.
16. Torchilin, V.P. et al. (2001). TAT Peptide on the Surface of Liposomes Affords their Efficient Intracellular Delivery even at Low Temperature and in the Presence of Metabolic Inhibitors. Proc Natl Acad Sci U S A 98 (15), 8786-8791.
17. Allen, T.M. et al. (2002). Use of the Post-Insertion Method for the Formation of Ligand-Coupled Liposomes. Cell Mol Biol Lett 7 (3), 889-894
18. Xiong, X.B. et al. (2005). Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin In Vitro Resulting in Improved Antitumor Activity In Vivo. Pharm Res 22 (6), 933-939.